Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients.

doi:10.1016/j.lungcan.2019.12.006

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients.

Lung cancer (Amsterdam, Netherlands) - 1 Feb 2020

Reale Maria Lucia, Chiari Rita, Tiseo Marcello, Vitiello Fabiana, Barbieri Fausto, Cortinovis Diego, Ceresoli Giovanni Luca, Finocchiaro Giovanna, Romano Gianpiero Diego, Piovano Pier Luigi, Del Conte Alessandro, Borra Gloria, Verderame Francesco, Scotti Vieri, Nonnis Daniela, Galetta Domenico, Sergi Concetta, Migliorino Maria Rita, Tonini Giuseppe, Cecere Fabiana, Berardi Rossana, Pino Maria Simona, Martelli Olga, Gelibter Alain, Carta Annamaria, Vattemi Emanuela, Pagano Maria, Zullo Alessandro, Ferrari Silvia, Rossi Antonio, Novello Silvia

Abstract excerpt

OBJECTIVES: Molecular diagnostics and care of non-small cell lung cancer (NSCLC) are continuously evolving. Few data document the current strategies to manage advanced NSCLC patients beyond progression in clinical practice. PATIENTS AND METHODS: Be-TeaM is an Italian multi-center observational study conducted on consecutive EGFR-mutated stage IV NSCLC patients, progressed during/after a first-line EGFR-TKI. It...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Carcinoma, Squamous Cell

Share to ErbB Receptors

Share to Molecular Targeted Therapy

Share to Neoplasm Metastasis

Share to Protein Kinase Inhibitors

Share to Survival Rate

Source

Open in PubMed

Identifiers

PMID: 31884129
DOI: 10.1016/j.lungcan.2019.12.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients.PMID 31884129Read ↗

Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study.Semantic proximity Read ↗

Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective.Semantic proximity Read ↗

Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study.Semantic proximity Read ↗

A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First or Second Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer: The ‘LUNGFUL’ StudySemantic proximity Read ↗

Liquid biopsy in clinical outcomes and detection of T790M mutation in metastatic non-small cell lung cancer after progression to EGFR-TKI.Semantic proximity Read ↗

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).Semantic proximity Read ↗

Real-world testing practices, treatment patterns, and outcomes of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor-mutated advanced/metastatic non-small cell lung cancer: An international study.Semantic proximity Read ↗

Molecular profiling of advanced non-small cell lung cancer in the era of immunotherapy approach: a multicenter Italian observational prospective study of biomarker screening in daily clinical practice.Semantic proximity Read ↗

BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study.Semantic proximity Read ↗

Real-World T790M Mutation Frequency and Impact of Rebiopsy in Patients With EGFR-Mutated Advanced Non-Small Cell Lung CancerSemantic proximity Read ↗

EGFR-mutation testing and TKI treatment patterns in locally advanced and metastatic NSCLC in Norway - A nationwide retrospective cohort study.Semantic proximity Read ↗

Clinical Outcomes Beyond 1L EGFR-TKI Progression in mNSCLC: Final Results of the Real-World Study 'LUNGFUL'.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.